Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 50 publications.

Buck P, Sweeney C, Georgieva M, Kunzweiler C, Tossonian H, Boyle K, Chirila C, Crawford R, Wolowacz S, Pesch M. Family spillover impact of congenital CMV in the United States and Canada: study methodology. Poster presented at the European Congenital Cytomegalovirus Initiative (ECCI) 2024; October 9, 2024. Leiden, the Netherlands.

Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovshka N, Hanson KA, Korver D, Chirila C. Patients with alopecia areata treated with ritlecitinib have improved patient-reported emotional symptoms and activity limitations due to hair loss: post hoc analyses of ALLEGRO-2b/3. Poster presented at the Maui Derm Hawaii 2024; January 22, 2024. Wailea, HI.

Yee KS, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Orphanet J Rare Dis. 2023 Nov 2;18(1):343. doi: 10.1186/s13023-023-02957-2

Garcia de Albeniz Martinez X, Chirila C, Hernan MA, Leaver DRM. Ready or not, here come estimands! The emerging attention to causal estimands in real-world evidence studies. Presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada.

Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno GA, Dollfus H, Chirila C, Gnanasakthy A, Buckley BC, Mallya UG, Clement K, Haqq AM. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023 Jan 16;18(1):12. doi: 10.1186/s13023-022-02602-4

Kummar S, Shen L, Martinus van Tilburg C, Tan DSW, Doz F, McDermott RS, Zwaan CM, Keating KN, Chirila C, Norenberg R, Fellous MM, Brega N, Xu R, Laetsch TW, Drilon AE, Hong DS. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. Poster presented at the 2022 ASCO Annual Meeting; June 3, 2022. Chicago, IL. [abstract] Am J Clin Oncol. 2022 Jun; 40(16_suppl):6563. doi: 10.1200/JCO.2022.40.16_suppl.6563

Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022 Feb 5;17(1):38. doi: 10.1186/s13023-022-02186-z

Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS. Quality of life in adult and pediatric patients with tropomyosin receptor kinase fusion cancer receiving larotrectinib. Curr Probl Cancer. 2021 Dec;45(6):100734. doi: 10.1016/j.currproblcancer.2021.100734

Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905

Forsythe E, Haws RM, Argente J, Beales P, Chirila C, Clement K, Dollfus H, Martos-Moreno GA, Gnanasakthy A, Buckley BC, Mallya U, Haqq AM. Quality of life in patients with bardet-biedl syndrome in a setmelanotide phase 3 trial. Poster presented at the 2021 Obesity Week Virtual Conference; November 1, 2021.

Kuhnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clement K. Quality of life in POMC or LEPR deficiency: setmelanotide phase 3 trials. Poster presented at the 2021 Virtual Overcoming Obesity Conference; October 14, 2021.

Chirila C, Odom D, Gnanasakthy A. Patient-reported outcomes assessment scheduling in oncology: are we introducing potential bias? Presented at the 2021 DIA Virtual Annual Meeting; June 27, 2021.

Yee KS, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Assessment of cognitive development in patients with neuronopathic Mucopolysaccharidosis II treated with intrathecal idursulfase-IT using Projected Retained Ability Score (PRAS): a post hoc analysis. Poster presented at the 2021 World Conference on Quality and Improvement; May 24, 2021.

Gandola AE, Ait Sarkouh R, Orfanos P, Bouisset F, Licitra L, Bourhis J, Mladsi D, Chirila C, Paret K, Barnett C. An early cost-effectiveness analysis of xevinapant in combination with chemo-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck in United States. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Yee K, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Using projected retained ability score to assess cognitive development in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Poster presented at the 2021 ACMG Annual Clinical Genetics Virtual Meeting; April 2021.

Magrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Understanding barriers in the pathway to diagnosis of ankylosing spondylitis: results from a US survey of 1690 physicians from 10 specialties. ACR Open Rheumatol. 2020 Oct;2(10):616-26. doi: 10.1002/acr2.11179

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab. Clin Drug Invest. 2019 Dec;39(12):1205-12. doi: 10.1007/s40261-019-00856-8

Margrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Recognition of inflammatory back pain by US healthcare providers and barriers to specialist referral. Poster presented at the 2019 ACR/ARP Annual Meeting; November 10, 2019. Atlanta, GA.

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y. A pilot study to assess the feasibility of a web-based survey to examine patient-reported symptoms and satisfaction in patients with ankylosing spondylitis receiving secukinumab. Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/S40801-019-0154-4

Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox, MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drilon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Poster presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(2019):6602.

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.

Thomas S, Chirila C, Ritchey MB. Visualization of patient electronic records to support exploratory analysis and variable derivation of categorical data. Presented at the 25th Annual SouthEast SAS Users Group (SESUG); November 2017. Cary, NC.

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Curr Med Res Opin. 2017 Aug;33(8):1457-66. doi: 10.1080/03007995.2017.1325730

Chirila C, Nuamah I, Woodruff K. Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials. Curr Med Res Opin. 2017 Jun;33(6):1083-90. doi: 10.1080/03007995.2017.1300144

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.

Muser E, Benson C, Chirila C, Graham J, Woodruff K. Resource use and cost in a randomized, non-inferiority trial of paliperidone palmitate 3 versus 1-month formulations in patients with schizophrenia. Poster presented at the 2016 American Psychiatric Association Annual Meeting; May 14, 2016. Atlanta, GA.

Chirila C, Zheng Q, Davenport E, Kaschinski D, Pfarr E, Hach T, Palencia R. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Qual Life Res. 2016 May;25(5):1199-207. doi: 10.1007/s11136-015-1140-2

Woodruff K, Chirila C, Zheng Q, Van Impe K, Nuamah I. Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: an analysis of phase III clinical trial hospital data. Poster presented at the 24th European Congress of Psychiatry; March 15, 2016. Madrid, Spain.

Bateman ED, Esser D, Chirila C, Fernandez M, Fowler A, Moroni-Zentgraf P, FitzGerald JM. Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: systematic review and network meta-analysis. J Allergy Clin Immunol. 2015 Oct;136(4):914-22. doi: 10.1016/j.jaci.2015.03.023

Wang J, Odom D, Chirila C, Zheng Q. Evaluation of matching-adjusted indirect comparison implemented by a resampling method. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Benson C, Chirila C, Graham J, Radder C, Zheng Q, Muser E, Woodruff K. Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Woodruff K, Chirila C, Sawyerr G, Nuamah I, Zheng Q. Healthcare resource use of paliperidone palmitate 3-month injection versus placebo: an analysis of the PSY-3012 phase 3 clinical trial hospital data. Poster presented at the American Psychiatric Association 168th Annual Meeting; May 2015. Toronto, Canada.

Chirila C, Ziemiecki RM, Davenport EK, Kaschinski D, Pfarr E, Palencia R. Health-related quality-of-life analysis for patients with type 2 diabetes mellitus treated with empagliflozin. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Odom DM, Chirila C, Sherrill EH, Wang J, Sherif BN. Practical issues when conducting network meta-analyses with a limited number of studies. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.

Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.

Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.

Mauskopf J, Chirila C, Masaquel C, Boye KS, Bowman L, Birt J, Grainger D. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013 Jan 1;29(1):92-100.

Bateman E, Esser D, Chirila C, Fernandez MM, Fowler A, Moroni-Zentgraf P, FitzGerald J. Systematic review and meta-analysis of the magnitude of the effect on the AQLQ and ACQ in asthma clinical trials. Poster presented at the ERS Annual Congress; 2013.

Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, Molnar I, Sherrill B. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis. 2012 May 1;27(5):623-34.

Chirila C, Gilligan TM, Gilsenan A, Price M, Hollis K, Calingaert B, Zografos L, Andrews E. A comparison of factors influencing patient knowledge: results across selected REMS surveys. Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 18, 2011. Chicago, IL.

Earnshaw SR, Chirila C, McDade CL, Black L, Andriole GL. Cost-effectiveness of dutasteride as a chemoprevention in prostate cancer: rEDUCE within-trial analysis. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011.

Mauskopf J, Chirila C, Masaquel CJ, Boye KS, Bowman L, Birt J, Grainger DB. The relationship between financial impact and the likelihood of drug reimbursement in the Australian health care system. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 26, 2011. [abstract] Value Health. 2011 May; 14(3):A22-3.

Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004

Chirila C, Odom D, Devercelli G, Khan S, Sherif B, Kaye J, Molnar I, Sherrill B. Meta-analysis of the validity of progression-free survival as a surrogate endpoint for overall survival in metastatic colorectal cancer trials. Poster presented at the 35th European Society for Medical Oncology Congress; October 12, 2010. [abstract] Ann Oncol. 2010 Oct; 21(suppl 8):623P.

Chirila C. Variable selection using random forests. Poster presented at the Midwest Biopharmaceutical Statistics Workshop; May 2008.

Hahn EJ, Rayens MK, Warnick TA, Chirila C, Rasnake RT, Paul TP, Christie D. A controlled trial of a quit and win contest. Am J Health Promot. 2005 Nov 1;20(2):117-26.

Chirila C, Wood CL, Stromberg AJ, Bathke A. An application of empirical processes to roc curves. Poster presented at the Joint Statistical Meetings; August 2005.

Hahn EJ, Rayens MK, Chirila C, Riker CA, Paul TP, Warnick TA. Effectiveness of a quit and win contest with a low-income population. Prev Med. 2004 Sep 1;39(3):543-50.